Companies Dominating the Lateral Flow Assays (LFA) Market
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Becton, Dickinson, and Company
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F.Hoffmann-La Roche AG
- QIAGEN N.V.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
- Merck kGaA
- PerkinElmer Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Abbott Laboratories announced the launch of a new lateral flow antigen test called the BinaxNOW COVID-19 Ag Card home test. This test is intended for non-prescription, and over-the-counter use, and provides results in 15 minutes. It is the first COVID-19 test authorized for non-prescription use by the US Reel and Drug Administration (FDA).
- Becton, Dickinson, and Company: SD announced the acquisition of a lateral now and clinical diagnostics company, Infiammatix. Inflammatix's technology enables rapid diagnosis and triage of patients with suspected infectious or inflammatory conditions. The acquisition is expected to enhance BD's diagnostic capabilities and expand its presence in the infectious disease market.
